Diclofenac consumption has been associated with significantly increased vascular and coronary risk in a study including coxib, diclofenac, ibuprofen and naproxen.<ref name="BhalaEmbersonEtAl">{{cite journal |last1=Bhala |first1=N. |last2=Emberson |first2=J. |displayauthors=etal |url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60900-9/fulltext |title=Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials |journal=The Lancet |volume=382 |issue=9894 |pages=769â€“779 |year=2013 |doi=10.1016/S0140-6736(13)60900-9 |pmid=23726390 |pmc=3778977}}</ref> Upper gastrointestinal complications were also reported.<ref name="BhalaEmbersonEtAl" /> Major vascular events were increased by about a third by diclofenac, chiefly due to an increase in major coronary events.<ref name="BhalaEmbersonEtAl" /> Compared with placebo, of 1000 patients allocated to diclofenac for a year, three more had major vascular events, one of which was fatal.<ref name="BhalaEmbersonEtAl" /> Vascular death was increased significantly by diclofenac.<ref name="BhalaEmbersonEtAl" />

 

